SMARCA4 and non-small cell lung carcinoma: Although little is known about the efficacy of ICIs for SMARCA4-alterated cancers, some case reports for patients with relapsed SCCOHT, SMARCA4-deficient thoracic sarcoma and SMACA4-altered non-small cell lung cancer have been published [19,20,21].